
Lixte Biotechnology Launches $4.3 Million Registered Direct Offering

I'm PortAI, I can summarize articles.
Lixte Biotechnology announced a $4.3 million registered direct offering of common stock, including pre-funded and investor warrants at $4.09 per unit. The offering comprises about 1.1 million units, each with one share of common stock or a pre-funded warrant, plus one common warrant. Proceeds will be used for general corporate purposes and working capital. The offering is expected to close by Friday. Lixte Biotechnology shares fell over 2% in recent trading.

